Compare Citius Pharmaceuticals Inc (CTXR) vs Devon Energy Corp (DVN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Devon Energy Corp — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while Devon Energy Corp trades at $49.15 (market cap $53.81B). The key difference: Devon Energy Corp is far larger — about 3950.8× Citius Pharmaceuticals Inc's market cap, and Devon Energy Corp pays a 2.62% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Devon Energy Corp for 136 Days on average.
| CTXR | DVN | |
|---|---|---|
Market Cap | $13.62M | $53.81B |
Volume | 132,438 | 11,556,740 |
Sector | Health | Energy |
52-Week High | $1.82 | $52.07 |
52-Week Low | $0.48 | $31.74 |
Typical Hold Time | 16 Days | 136 Days |
Enterprise Value | $3.79M | $64.55B |
Dividend Yield | — | 2.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
Devon Energy (DVN) trades at $47.88, down 0.29% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $62.40 implying significant upside. Recent earnings have been mixed, with a Q2 2026 beat but a Q1 miss, while fundamentals show solid profitability with a 16.67% net income margin and attractive valuation multiples. Activist investor pressure for strategic alternatives, including a potential sale, has been a key recent development.
The outlook is positive, supported by strong analyst buy ratings (71.87%) and projected revenue growth to $19.7B in 2026. Key risks include oil price volatility, execution of asset sales, and rising debt levels, but the current valuation and cash flow generation present a compelling opportunity for value-oriented investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Devon Energy Corp
Devon Energy, based in Oklahoma City, is one of the largest independent exploration and production companies in North America. The firm's asset base is spread throughout onshore North America and includes exposure to the Delaware, STACK, Eagle Ford, Powder River Basin, and Bakken plays. At year-end 2021, Devon's proved reserves totaled 1.6 billion barrels of oil equivalent, and net production that year was 572 thousand boe/d, of which oil and natural gas liquids made up 74% of production, with natural gas accounting for the remainder.
Read more on DVN →
